Skip to content

Efficacy of Montelukast to prolonged cough.

Efficacy of Montelukast to prolonged cough. - Efficacy of Montelukast to prolonged cough.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002360
Enrollment
50
Registered
2009-08-21
Start date
2009-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prolonged cough

Interventions

Fluticason propionate is administrated. Montelukast is administrated.

Sponsors

Kansai Asthma Research Network(KARN)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1, Sex and age : No object. 2, Hospitalization or out patients : No object. 3, Non-smoking patient (By prohibition of smoking and past history of cigarette smoking include a smoking patient within 10pack-year more than three months). 4, Prolonged and/or chronic cough was continuing more than three weeks. 5, The patient who was able to acquire an agreement by the document.

Exclusion criteria

Exclusion criteria: 1, Patients with the shadow by chest X-rays. 2, Patients who heard fine crackle. 3, Patients that consultation two weeks later is impossible. 4, Patients who give a clear asthma attack. 5, Patients who merges heart failure. 6, Patients who is running a fever. 7, Patients who is infected with serious respiratory illnesses such as activity-related tuberculosis or lung cancer. 8, ACE inhibitor taking patients. 9, Side effect that is serious for an ingredient of the study medicine or a patient with the anamnesis of the erythrism. 10,Patients whom it was judged a doctor not to be suitable as an object of the studies.

Design outcomes

Primary

MeasureTime frame
Change rate of cough score.

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026